- Generally healthy men and women with persistent asthma, 18 to 70 years of age, with
body weight between 50 kg and 115 kg.
- History of treatment with a medium to high dose of inhaled corticosteroids (ICS), with
or without long-acting beta-agonists (LABA), for at least 2 months prior to the
screening visit and must remain constant during the study.
- FEV1 ≥ 55% to ≤ 80% predicted and demonstrated improvement in FEV1 (L) with inhaled
albuterol (salbutamol) (reversibility) of ≥ 12%.